THERAPY DOSSIER · th-eb6665c2c6ac

LY2109761

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22547771 ↗2012Reported benefit

LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-beta and BMP-associated proinflammatory and proangiogenic signals.

MouseRadiationC57BL/6FemaleOralFour weeks of dosing given either before, during or after irradiation

Model: Single-dose 20 Gy thoracic irradiation causing pneumonitis and pulmonary fibrosis

LY2109761 markedly reduced radiation-induced inflammation and pulmonary fibrosis and prolonged survival, suppressing canonical and non-canonical TGF-beta and BMP signalling as well as inflammatory (IL-6, IL-7R, IL-8) and proangiogenic (ID1) genes.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…